BMS-986207

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Broad Solid TumorNon-Small Cell Lung Cancer

Phase 1

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

CompletedNCT02913313

Bristol-Myers SquibbBroad Solid Tumor

Start: 2016-11-30End: 2024-01-25Updated: 2025-04-20

Phase 2

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

CompletedNCT05005273

Bristol-Myers SquibbNon-Small Cell Lung Cancer

Start: 2022-10-03End: 2022-12-27Updated: 2024-02-28

Related Papers

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations